// App-Quantinova.ai

228 : ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Simon J. Crabb

Principal Investigators

  • Alison J. Birtle

  • Karen Martin

  • Nichola Downs

  • Megan Bowers

  • Ian Ratcliffe

  • Mary Ellis

  • Gareth Griffiths

  • Stuart Thompson

  • Vincent Khoo

  • Robert J. Jones

Medical Centers

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust, Manchester, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Patient and Public Involvement Representative, Southampton, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Prednisolone

  • Docetaxel

  • AZD-5363

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02121639

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved